INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.43 USD | +14.40% |
|
+15.32% | -12.27% |
| 05-08 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-21 | Transcript : InflaRx N.V. - Special Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 600K 650K 886K | Sales 2025 * | 1.71M 1.86M 2.53M | Capitalization | 77.84M 84.31M 115M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -49.82M -67.92M | Net income 2025 * | -61M -66.07M -90.07M | EV / Sales 2024 * | 43.8 x |
| Net cash position 2024 * | 51.55M 55.83M 76.12M | Net cash position 2025 * | 7.3M 7.9M 10.77M | EV / Sales 2025 * | 41.2 x |
| P/E ratio 2024 * |
-1.79
x | P/E ratio 2025 * |
-1.54
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 day | +14.40% | ||
| 1 week | +15.32% | ||
| Current month | +4.38% | ||
| 1 month | -4.67% | ||
| 3 months | -2.72% | ||
| 6 months | -4.67% | ||
| Current year | -12.27% |
1 week
1.17
1.47
1 month
1.171.47
Current year
1.172.10
1 year
1.145.05
3 years
0.787.25
5 years
0.7843.34
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 1.43 | +14.40% | 300,648 |
| 24-05-13 | 1.25 | +5.93% | 145,253 |
| 24-05-10 | 1.18 | -1.67% | 226,429 |
| 24-05-09 | 1.2 | 0.00% | 306,652 |
| 24-05-08 | 1.2 | -3.23% | 264,912 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-06-05
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.322
EUR
Average target price
8.375
EUR
Spread / Average Target
+533.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.27% | 84.2M | |
| +5.33% | 111B | |
| +12.11% | 106B | |
| -12.56% | 22.24B | |
| -3.70% | 21.25B | |
| -6.03% | 18.97B | |
| -35.21% | 18.52B | |
| -10.86% | 16.81B | |
| +5.10% | 13.94B | |
| +37.57% | 12.54B |
- Stock Market
- Equities
- IFRX Stock
